Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» plamotamab
plamotamab
J&J spends $100M upfront, with $1.2B in biobucks, to join Roche and Regeneron in bispecific blood cancer race
Fierce Biotech
Mon, 10/4/21 - 11:08 am
JNJ
Xencor
biobucks
Roche
Regeneron
bispecific antibodies
blood cancers
plamotamab